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Summary The clinical course of breast cancer was related to degree of anaplasia (DA) and steroid receptor
(SR) content of primary tumours in 743 patients (pts) with clinical recurrence, initially enrolled in the DBCG-
77 protocols. The oestrogen receptor (ER) and the progesterone receptor (PgR) content was known in 110
and 67 pts. The recurrence-free interval, survival after recurrence, and the overall survival were all prolonged
in patients with well differentiated tumours or with high SR content.
The tumour growth rates were estimated as clinical rates of progression (i.e., the time elapsed from a single
distant metastasis until dissemination). The progression rate was prolonged in relatively well differentiated as
well as in receptor rich tumours. The extent of dissemination, as indicated by the number of metastatic sites,
was not associated with either DA or SR content. However, the anatomical distribution of metastases varied
with both DA and SR content: signs of poor prognosis (high DA or low SR content) were associated with
occurrence of visceral metastases. In contrast, SR rich tumours had a propensity for recurrence in bone. The
results suggest that the impact on prognosis of the features examined here includes both variations in growth
rate and metastatic pattern.
In general, breast cancer is a subclinical disseminated disease
at the time of initial diagnosis, and in most patients disease
is expected to recur. Although the ultimate outcome of the
disease can thus be predicted for most patients, there are
considerable variations in length of survival (Brinkley &
Haybittle, 1975).
Subsets of patients with breast cancer who have approxi-
mately the same expected survival time can be identified by
means of various features of the patients or their primary
tumours (i.e., prognostic factors). Generally, such factors are
considered to reflect metastatic potential or growth rate.
However, supplementary interpretations of these prognostic
factors may reveal that their impact on survival is mediated
through differences in extent and/or anatomical location of
recurrent disease. According to this concept, different pro-
gnostic characteristics may predict different metastatic
patterns.
Dissimilarities in both the degree of anaplasia (DA) and
steroid receptor (SR) content of the primary tumour proba-
bly influence prognosis by differences in growth rate. Thus,
less differentiated tumours and tumours with a low receptor
content have a higher growth rate (Meyer et al., 1986;
Adami et al., 1985) and, consequently, a shorter survival
(Schnuerch et al., 1985; Heuson et al., 1977) than higher
differentiated and receptor rich tumours. However, varia-
tions in prognosis with DA and SR content may also reflect
differences in the pattern of spread. The present study was
undertaken to examine whether such relationships exist.
Materials and methods
Criteria of selection
All patients had initially operable breast cancer and partici-
pated in the 77 protocols of the Danish Breast Cancer
Cooperative Group (DBCG) study of primary treatment and
follow up (Andersen et al., 1981). They were all followed at
one of the participating oncological centres or at the regional
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medical or surgical departments. The confirmative diagnosis
of recurrent disease and subsequent treatment was under-
taken by the oncological centres.
The primary treatment was total mastectomy with partial
axillary dissection. Patients were divided into a high and a
low risk group: Low risk patients had tumours <5 cm in
diameter, no positive nodes, and no invasion of skin or
fascia. These patients received no further therapy following
mastectomy. The high risk patients had tumours >5cm in
diameter and/or positive lymph nodes and/or skin or fascial
invasion. These patients received postoperative radiotherapy
to the chest wall, the axillary and periclavicular areas
equivalent to 1335 rets, and were further randomized to
different forms of systemic adjuvant treatments as described
in detail elsewhere (Andersen et al., 1981; Kamby et al.,
1988).
All patients were seen for physical examination every 3
months until 18 months after mastectomy, and every 6
months thereafter. Chest X-rays, bone scintigraphy, and
blood chemistry were carried out every 6 months for one
year. Thereafter, chest X-rays were repeated once a year for
another 4 years. Abnormal bone scintigram required bone
X-ray survey.
Treatment of recurrent disease
Low risk patients with locoregional recurrence received
radiotherapy. High risk patients with locoregional recurrence
and all patients with distant metastases were treated
according to menopausal status and age. Premenopausal
patients were castrated and received a 3 drug chemotherapy
combination with cyclophosphamide, adriamycin and 5-
fluorouracil. Postmenopausal patients below the age of 65
years received tamoxifen and a 3 drug chemotherapy combi-
nation with cyclophosphamide, methotrexate or adriamycin,
and 5-fluorouracil. Patients above 65 years of age received
endocrine therapy only.
All mastectomy specimens were macroscopically and
microscopically evaluated at the local pathological depart-
ments, according to uniform protocolled guide lines. The
histological evaluation of primary tumour included histo-
logical typing according to WHO recommendations (Scarff,
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1968). The ductal carcinomas NOS were classified as well
(DA =I), medium (DA =II), and poorly (DA =III) differ-
entiated, according to the grading system of Bloom &
Richardson (1957), using the following histologic factors: (1)
tubule formation; (2) pleomorphism, and (3) mitotic nuclei.
The SR content was measured by a dextran-coated char-
coal assay in a single laboratory according to the methods
recommended by the EORTC (EORTC Breast Cancer
Cooperative Group, 1980). Tumours were considered posit-
ive when at least 10fmolmg-1 cytosol protein were present.
When analyzing the SR contents semiquantitatively, the
following scale was used: low content: < 10 fmolmg-1, inter-
mediary content: 10-99fmolmg-1, and high content:
>100fmolmg-1. The SR content was in all cases measured
in histologically verified malignant tissue from the primary
tumour. Due to geographical and temporal restrictions (i.e.,
SR analyses were started in September 1979), the SR
contents were known in only 13% of the patients. Therefore,
the period of observation after recurrence was shorter for SR
determined patients compared with patients without SR
determination. Patients with and without SR determination
were comparable with respect to age, menopausal status,
stage and type of adjuvant systemic treatment (data not
shown).
All metastatic sites detected within one month after diag-
nosis of the first site of metastasis were grouped together
and designated as the sites of metastases at the time of first
recurrence. Subsequent metastases in other sites, the dates of
their detection, and the treatment were recorded. These
metastases, together with the metastatic sites of first recur-
rence, were grouped and defined as the cumulated sites of
recurrence at the time of follow up.
The sites of metastases were divided into the following
categories: local skin recurrence (skin and/or subcutaneous
tissue of the ipsilateral mammary region); other skin recur-
rence (skin and/or subcutaneous tissue outside the ipsilateral
mammary region); regional lymph node recurrence (RLN;
regional lymph nodes of the ipsilateral axilla or peri-
clavicular region); other lymph node metastases (OLN; lymph
nodes other than RLN). Contralateral breast tumours (all
carcinomas in the contralateral breast were regarded as
recurrences of the primary tumour). Bone metastases (veri-
fied by X-rays). Lung and pleural recurrences (demonstrated
by X-ray examination; solitary pleural effusion required
cytological verification). Liver metastases (demonstrated by
ultrasound or CT scan). Brain metastases (confirmed by
brain scintigraphy or CT scan). The number of metastatic
sites was defined as the number of above-mentioned anato-
mical locations with metastases, irrespective of the number
of deposits within each site. In the case of bone metastases,
information about the number, the localization, and the
radiographic morphology was obtained from the radiology
reports.
The incidence of metastases in a specific anatomical site
was evaluated in the following 5 ways: (1) at the time of first
recurrence, (2) as the only site at first recurrence, (3) at the
time of evaluation, (4) as the only site of recurrence at the
time of evaluation, and (5) within the first year after
mastectomy.
The period of follow up was defined as the time from
mastectomy until the date of evaluation (autumn 1984). The
recurrence-free interval (RFI) and the overall survival (OS)
were calculated from mastectomy until the date of recurrence
(RFI) or death (OS). The survival after recurrence (SAR)
was defined as the time from first recurrence until death.
The tumour growth rate was estimated from life table
analyses as the time to progression. The time to progression
was defined as the interval from initial recurrence in a single
distant site until detection of other distant metastases. Thus,
the three year actuarial proportions of patients with subse-
quent metastasis were used as measurements for comparisons
of progression rates between DA = I, II, and III. When
comparing the SR: contents, we used the two year actuarial
proportions, since the period of observation was shorter for
the SR determined subgroup of patients (cf. above).
Comparisons of the frequencies of metastases were per-
formed by the Chi-square or the rank t-test (Mann-Whitney
rank sum test) for ordered categories (Bartolucci, 1984;
Bross, 1954). The Mantel-Haenszel chi-square statistics
extended for stratified data was used in order to control for
the possible confounding effect of stage, DA, and SR
(Kleinbaum et al., 1982). Actuarial life table analyses have
been performed on all data concerning RFI, OS, SAR, and
progression time. The log rank test was used to evaluate
differences between survival curves (Peto et al., 1977). A
two-tailed P value of <0.05 was considered significant.
Results
Patient characteristics
The median time (range) of follow up from initial diagnosis
was 4.9 years (2.0-7.0), and the median (range) period of
observation after recurrence was 3.6 years (0.8-6.4). A total
of 863 patients with clinical recurrence met the criteria of
selection. Table I shows the distribution of these patients
according to menopausal status, primary stage, and type of
systemic adjuvant therapy.
Degree of anaplasia
The DA of the primary tumour was known in 743 patients
(86%). Of these, 133 patients (18%) had grade I, 431
patients (58%) had grade II, and 179 patients (24%) had
grade III tumours. Fourteen percent of the 863 patients with
clinical recurrence could not be graded, because their
tumours were not ductal.
Survival Patients with low differentiated tumours had a
shorter OS than patients with higher differentiated tumours.
The reduction in OS comprised both a reduction of RFI
(P=0.0001) and SAR (P=0.0001) of stage II patients,
whereas only RFI was effected in stage I patients (P=0.02).
The actuarial three year survival rates according to DA I, II,
and III were 93%, 89%, and 89% in patients with stage I
(P=0.06), and 91%, 76%, and 63% in stage II patients
(P=0.0001). Grade III tumours occurred more often in
patients with stage II disease than they did in stage I patients
(P<0.0001; rank t-test).
Metastatic pattern Most patients recurred initially in a
single site. There were no differences in the number of
metastatic sites between groups of patients with tumours of
different DA's (Table II). The most common site of first
metastasis was bone (36% of all patients with recurrence),
followed by recurrence in lung (24%) and local skin (22%).
The incidence of visceral metastases was increasing with
increasing DA, whereas the distribution of soft tissue and
bone metastases was unassociated with DA, both at the time
of first recurrence (Figure 1) and at the time of evaluation
Table I Distribution of patients with recurrence according
to stage, menopausal status, and type of systemic adjuvant
therapy
N (%)
Total number of patients 863 (100)
Stage I 228 (26)
Stage II 635 (74)
Premenopausal 319 (37)
Postmenopausal 544 (63)
Systemic adjuvant therapy:
- none 479 (55)
- Levamisole 96 (11)
- Cytotoxic agents 134 (16)
- Tamoxifen 154 (18)482 C. KAMBY et al.
Table II Distribution of patients according to number of metastatic
sites at the time of first recurrence and degree of anaplasia of the
primary tumour. N (%) indicates the number of patients with
recurrence in each group
Degree of anaplasia
I II III
Number
of sites N (%) N (%) N (%)
1 100 (75) 306 (71) 123 (69)
2 22 (17) 82 (19) 32 (18)
>3 11 (8) 43 (10) 24 (13)
TOTAL 133 (100) 431 (100) 179 (100)
P=0.38 (Kruskal-Wallis test).
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Figure 1 Anatomical distribution of metastases at the time of
first recurrence according to degree of anaplasia (DA) of the
primary tumour. Heights of the columns represent occurrence
(%) of metastases in relation to the total number of patients (N)
in each stratum.
(Figure 2). In patients with a single site offirst recurrence,
both recurrences of OLN and liver were more common in
patients with DA =III tumours than in patients with
tumours of lower DA's (P<0.05; data not shown). More-
over, in patie-ifs with a single site of metastases at the time
of evaluation, only liver metastases occurred more often in
patients with tumours of higher DA (P<0.05; data not
shown).
Temporal relations Two hundred and forty-eight (33%) of
the 743 patients with clinical recurrence had their first
recurrence within the first year after mastectomy. As
expected, there was a significant trend for patients with
tumours in higher DA to have recurrence earlier than
patients with tumours of lower DA (P=0.00002). The
anatomical distribution of metastases among patients recur-
ring within the first year after mastectomy is presented in
Table III: OLN recurrences and liver metastases occurred
more often among patients with DA=111 tumours compared
to patients with primary tumours of lower grades (P<0.05).
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Figure 2 Anatomical distribution of metastases at the time of
follow up according to degree of anaplasia (DA) of the primary
tumour. For interpretation, see legend to Figure 1.
Table III Distribution of patients with recurrence within the 1st
year after mastectomy according to degree of anaplasia and anato-
mical site of recurrence. N indicates the total number of patients in
each group
Degree of anaplasia
I II III
N=32 N=143 N= 73
Local skin 6 33 19
Other skin 2 6 7
Regional lymph nodes 4 25 13
Other lymph nodes 0 8 13*
Contralateral breast 2 9 3
Bone 10 58 13
Lung 6 27 19
Pleura 2 17 9
Liver 1 21 14*
Brain 1 3 2
*P<0.05 (rank t test).
The progression time (I.e., interval between first and subse-
quent distant metastases) was shorter for patients with grade
II and III tumours than for patients with grade I tumours.
Thus, although the differences are not statistically signifi-
cant, more than 40% of the grade II and III patients
developed multiple distant metastases within 3 years com-
pared to 21% of the grade I patients. There were no
differences in type of adjuvant treatment and treatment of
advanced disease among patients with different DA
(P=0.25) (Table IV).
Steroid receptor data
The ER content of the primary tumour was determined in
110 of the 863 patients; 35 patients (32%) had
<10fmolmg-1, 44 patients (40%) had 10-99fmolmg-1,
and 31 patients (28%) had .100fmol ERmg-1 cytosol
protein. The PgR content was measured in 67 of the patients
with recurrence; 29 patients (43%) had <10fmolmg-1, 21
patients (31%) had 10-99fmolmg-1, and 17 patients (25%)
had .100fmol PgRmg-1 cytosol protein.
Survival Prolonged RFI (P=0.001), SAR (P=0.0050), and
OS (P=0.0004) were associated with increasing ER concen-
trations. The same pattern applied to PgR determined
patients with respect to SAR (P=0.0062) and OS
(P=0.0554), but not to RFI (P=0.2155). (All P values
derive from log rank tests: low vs. intermediate vs. high SR
content, degree of freedom: 2). The SR content was compar-
able in patients with stage I and II tumours (ER: P=0.82;
PgR: P=0.42; rank t-test).
Metastatic pattern The ER and PgR content of the primary
tumour did not predict the number of metastatic sites either
at the time of first recurrence (P=0.47 and P=0.35, respec-
tively) or at the time of follow up (P=0.44 and P=0.10,
respectively). (P values derive from rank t-tests: low SR
content vs. intermediate or high SR content).
The anatomical distribution of metastases at the time of
first recurrence is presented according to SR status in
Figures 3 and 4. There was a propensity for receptor positive
tumours to recur in bone (P<0.05), while ER negative
tumours more often recurred in lung, liver, and brain. When
the ER data were analyzed semiquantitatively, it was found
that while the incidence of contralateral breast tumours
increased with increasing ER concentrations, visceral meta-
stases occurred more often among patients with low ER
content (Table V). These differences were also found at the
time of evaluation. The anatomical distribution of metastases
according to PgR content was in agreement with the ER
data except for contralateral breast and lung (small
numbers). Thus, although the numbers are small, the data
show a tendency for tumours with high PgR content to recur
in bone, and with low PgR content to recur in the liver. ThePATTERN OF METASTASES IN BREAST CANCER 483
Table IV Distribution of patients with a single distant site of recurrence according to the degree of
anaplasia, type of therapy, and proportions of patients with progression within 3 years after recurrence
Three-year actuarial
Type of therapy cumulated proportion
Degree of Total no. of ofpatients with
anaplasia patients EP cT" ET+CT Other progression (%)
I 74 29 11 25 9 (21)
II 230 85 18 91 36 (42)
III 89 37 7 29 16 (46)
'ET=endocrine therapy; bCT=chemotherapy.
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Figure 3 Anatomical distribution of metastases at the time of
first recurrence according to oestrogen receptor (ER) status of
the primary tumour. For interpretation, see legend to Figure 1.
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Figure 4 Anatomical distribution of metastases at the time of
first recurrence according to progesterone receptor (PgR) status
of the primary tumour. For interpretation, see legend to Figure 1.
anatomical distribution of metastases was not associated
with SR status in the group of patients recurring within the
first year after mastectomy, and among patients with only
one site of recurrence.
Thirty-seven (34%) of the ER and 23 (34%) of the PgR
determined patients had bone metastases. More than 75% of
these were located in the spine, and metastases were confined
to a single bone region in more than half of the patients.
The extent and location of bone metastases was not asso-
ciated with the SR content (Table VI). Osteolysis, which was
the most dominating radiographic morphology, occurred in
76% of the patients with bone metastases; osteosclerosis in
24%, and mixed bone metastases in 14% of the patients.
Osteolytic metastases were found more often among patients
with low or intermediate ER content than among patients
with high ER content (P<0.05).
Progression time The proportion of patients with a single
distant recurrence who subsequently developed other distant
metastases is presented according to SR content in Table
VII. The proportions are actuarial percentages of patients
progressing within 2 years. The proportion increased with
both decreasing ER (P=0.012) and PgR content (P=0.003).
The treatment of these patients was not dependent on either
the ER content (+/- chemotherapy: P=0.31; +/- endo-
crine therapy: P=0.24) or the PgR content (P=0.25 and
P=0.58, respectively).
Discussion
We have investigated the clinical course of primary and
recurrent breast cancer in relation to two established prog-
nostic factors. The aim was first to confirm the impact of the
DA and the SR content on prognosis. Secondly, it was the
Table V Distribution of patients according to semiquantitative oestrogen receptor receptor (ER) content of the primary tumour
and the anatomical sites of metastases at the time of first recurrence and at the time of evaluation. Figures are total number of
patients in each group, N, with percentages in parentheses
Ist recurrence Follow up
ER content, fmolmg- ER content,fmolmg-
<10 10-99 .100 <10 10-99 .100
N (%) N (%) N (%) N (%) N (%) N (%)
Number of patients
with recurrence 35 (100) 44 (100) 31 (100) 35 (100) 44 (100) 31 (100)
Sites of recurrences:
Skin, local 9 (26) 8 (18) 13 (42) 10 (29) 11 (25) 13 (42)
Skin, other 4 (11) 1 (2) 3 (10) 6 (17) 5 (11) 4 (13).
Regional lymph nodes 5 (14) 10 (23) 1 (3) 8 (23) 11 (25) 4 (13)
Other lymph nodes 2 (6) 5 (11) 0 (0) 4 (11) 6 (14) 0 (0)
Contralateral breast 0 (0) 3 (7) 3 (10) 1 (3) 4 (9) 5 (16)
Bone 6 (17) 20 (45) 11 (35) 10 (29) 26 (59) 14 (45)
Lung 10 (29) 9 (20) 6 (19) 12 (34) 10 (23) 6 (19)
Pleura 2 (6) 3 (7) 3 (10) 4 (11) 7 (16) 3 (10)
Liver 7 (20) 5 (11) 1 (3) 10 (29) 7 (16) 1 (3)
Brain 2 (6) 1 (2) 0 (0) 6 (17) 1 (2) 0 (0)
*
* lc. - - 1. - -484 C. KAMBY et al.
Table VI Radiographic pattern of bone metastases according to the steroid receptor content of the primary
tumour
ER' content, fmolmg- PgRb content, fmolmg 1
<10 10-99 > 100 <10 10-99 > 100
Total no. of patients 6 20 11 8 7 8
No. of bone regions with metastases
- single 4 11 7 4 3 5
- multiple 2 9 4 4 4 3
Localization within the skeleton
- cranium 0 2 3 0 0 0
- columna 5 17 8 7 6 5
- pelvis 2 11 5 4 5 3
- thorax 0 8 4 1 3 2
- extremities 1 8 5 1 4 2
Radiographic morphology
- osteolysis 4 20 4 6 7 6
- osteosclerosis 1 4 4 2 3 0
- mixed 1 1 3 0 1 3
aER=oestrogen receptor; bPgR=progesterone receptor.
Table VII Steroid receptor content of the primary tumour according to the two-year actuarial
cumulated proportion (ACP) of patients, who after initial recurrence in a single distant site
developed additional metastatic sites
ER determined patients PgR determined patients
Steroid receptor content,
fmolmg1Iva ACP % Na ACP %
<10 21 44 15 50
10-100 28 15 13 14
>100 17 0 13 8
P (log rank) 0.012 0.029
N=number of patients.
Figure 5 Line diagram showing that the mechanisms of action
of prognostic factors can be ascribed to chronological and
biological circumstances: Biological differences may manifest
themselves by variations in pattern of metastases or in growth
rate. The parameters used in this study to evaluate biological
differences are shown below the dotted line.
purpose to elucidate whether the prognostic effect of these
features also reflects different clinical manifestations of the
disease, since differences such as metastatic extent and
progression rate may reflect basic biological tumour charac-
teristics. Moreover, a connection between a prognostic vari-
able and a certain metastatic pattern and/or growth rate
could suggest a specific mechanism of action of the prognos-
tic factor. According to this working hypothesis, which is
outlined in Figure 5, the finding of a uniform metastatic
pattern and growth rate between prognostic strata indicates
that differences in tumour age may play a major role (i.e.,
chronological prognostic factors).
Histological grading techniques involve subjectivity, and
only between 60% and 77% of the results can be reproduced
(Stenkvist et al., 1979). Data concerning DA were extracted
from the DBCG data base. Tumour grading was not
reviewed for the present study, and this may introduce
statistical 'noise'. However, from a statistical point of view,
random inaccuracies in the measurement of a variable can
mask an existing correlation but cannot create an artefactual
relationship. Moreover, the result of tumour grading from
the DBCG-77 programme has prognostic significance
(Andersen et al., 1981; Rank et al., 1987). Thus, despite the
multi-institutional basis of the material, the classification
according to DA may reflect division of tumours in biologi-
cal entities. While data on tumour grade are available for
84% of the patients with recurrence, receptor data are
available for only 15% of the patients. Although patients
with and without receptor measurements were without differ-
ences with regard to the occurrence of important prognostic
factors, the results of the anafysis of grade would appear to
be more reliable than those for receptor status.
The study confirms that survival from initial diagnosis is
related to both the DA and the SR content of the primary
tumour (Schnuerch et al., 1985; Heuson et al., 1977). The
reduced survival of patients with either low differentiated or
receptor poor tumours applied to a shortening of both RFIPATTERN OF METASTASES IN BREAST CANCER 485
and SAR compared to patients with either high differen-
tiated or receptor rich tumours. This indicates that differ-
ences in the status of either DA or SR reflect tumours with
different growth rates, and it is further supported by the
findings of progression times, which vary with both DA and
SR content. The reduced growth rate with increasing SR
content may partly be explained by increasing response rates
and response durations for patients who received endocrine
therapy. However, it seems likely that the SR content also
reflects basic growth rate, since the proliferative rate, esti-
mated by the thymidine labelling index, TLI, increases with
decreasing SR and increasing DA (Meyer et al., 1986; Adami
et al., 1985) and since the TLI is related to prognosis
(Strauss et al., 1982).
Patients with different stages of primary breast cancer are
supposed to have tumours of different ages (Kamby et al.,
1987). Thus, stage of disease may be regarded as a chrono-
logical prognostic factor. Higher grades of anaplasia were
more common in patients with stage II than stage I tumours.
The influence of DA on prognosis may, therefore, also
contain an element of tumour chronology. In contrast, since
the SR content of the primary tumours was not associated
with stage, the impact on survival of SR content does not
seem to include differences in tumour age.
In recurrent breast cancer, the prognosis (i.e., the SAR) is
among other factors influenced by the anatomical location
and the number of recurrences (Vincent et al., 1986;
Hietanen et al., 1986). Since SAR in the present study was
related to both DA and SR content of the primary tumour,
it seems plausible that the influence on prognosis of these
factors may be mediated through variations in the pattern of
dissemination. However, since the number of anatomical
regions with metastases was unassociated with both DA and
SR content, it is unlikely that the effect on SAR is mediated
through differences in the extent of dissemination. When
analyzing the distribution of metastases, however, it was
found that initial signs of poor prognosis also reflect the
appearance of metastases in organs where lethality would be
greater (i.e., brain, liver, and lung), and that receptor
positive patients had a propensity for developing bone
metastases compared to receptor negative patients. The
increased incidence of liver metastases among patients with
low differentiated tumours confirms the findings of Bunting
et al. (1976) and Coleman & Rubens (1987). More-
over, the literature shows that ER negative tumours prefer-
entially metastasize to viscera (Campbell et al., 1981; Qazi et
al., 1984; Singhakowinta et al., 1980; Samaan et al., 1981),
while ER positive tumours metastasize to bone (Campbell et
al., 1981; Qazi et al., 1984; Singhakowinta et al., 1980; Walt
et al., 1976, Stewart et al., 1981; Clark et al., 1987; Williams
et al., 1987).
The different metastatic patterns of tumours with varying
degrees of tumour differentiation and SR content support
experimental data concerning clonal evolution and metasta-
sis. According to these, the appearance of clinical metastases
is the end result of a process, where selection, adaptation,
and growth of tumour cells in various organs lead to
progressive heterogeneity between both the primary tumour
and the metastases, and between metastases in various
organs (Nowell, 1976; Poste & Fidler, 1980). Thus, the
propensity of ER positive tumours to recur in the contra-
lateral breast may suggest a growth lead of these tumours
compared to ER negative tumours. Moreover, as the hormo-
nal microenvironment of the contralateral breast is expected
to facilitate growth of ER rich tumour cells, tamoxifen
treatment may reverse this. In accordance with this view, a
reduced incidence of contralateral breast tumours was found
in tamoxifen treated patients from the NATO trial (Cuzick
& Baum, 1985).
Why SR rich tumours tend to recur more often in bone is
not known. Since ER positive tumour cells are capable of
inducing osteolysis in vitro (Valentin-Opran et al., 1985),
these cells may have a survival advantage in the bone system
when compared to ER negative cells. In the present study,
radiographic osteolysis was more often found in ER negative
patients. Since endocrine therapy inhibits the growth of SR
rich tumours, and since osteosclerosis may be an indicator of
tumour cell response to endocrine therapy (Coombes et al.,
1983), the radiographic appearance of osteosclerotic bone
metastases in SR positive patients and the appearance of
osteolysis in SR negative patients are compatible with the
present findings.
The inclusion of tamoxifen treated patients in the current
study probably does not introduce bias, because randomiza-
tion resulted in equal SR contents in tumours of treated and
untreated patients, Because of low number of receptor
determined patients it was not possible to analyze the
metastatic pattern in relation to both the type of adjuvant
systemic treatment and SR status at the same time. We have,
however, previously reported (Kamby et al., 1988b) that
failures of adjuvant tamoxifen treatment often involve
appearance of lung metastases. This is in agreement with the
present results, since ER negative tumours disseminate to
lung more often than do ER positive tumours.
In conclusion, it is most likely that the influence on
prognosis of tumour grade and SR content works through
multiple 'mechanisms'. Of these, biological growth properties
such as growth rate and metastatic pattern are probably of
greatest importance. The acknowledgement of site specific
differences in SR content has implications for rational
application of endocrine therapy. Thus, one should not
regard patients as either receptor positive or negative, based
on primary tumour determinations only. Instead, SR mea-
surements should be performed on metastases in various
locations before deciding on treatment.
Supported by a grant from the Danish Medical Research Council
no. 12-6006.
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